Albany Molecular Research, Inc. (AMRI) Tops Q2 EPS by 1c, Offers Q3 and FY11 Contract Revenue Guidance
Tweet Send to a Friend
Albany Molecular Research, Inc. (NASDAQ: AMRI) reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
